New cell therapy tested for Tough-to-Treat blood cancer
NCT ID NCT07294625
Summary
This early-stage study is testing a new cell therapy called LVIVO-TaVec200 for patients with multiple myeloma that has come back or stopped responding to standard treatments. The study aims to find a safe and effective dose and see how the body handles the treatment. It is for adults who have already tried at least three other therapies for their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hospital
NOT_YET_RECRUITINGZhengzhou, Henan, China
Contact
-
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, China
Contact
-
The Affiliated Hospital of XUZHOU Medical University
NOT_YET_RECRUITINGXuzhou, Jiangsu, China
Contact
-
The First Affiliated Hospital with Nanjing Medical University
RECRUITINGNanjing, Jiangsu, China
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Second Affiliated Hospital of Xi'an Jiaotong University
NOT_YET_RECRUITINGXi’an, Shanxi, China
Contact
Conditions
Explore the condition pages connected to this study.